University of Kansas Medical Center, Childrens Mercy to offer COVID-19 vaccine trial – KMBC Kansas City

KANSAS CITY, Kan.–.
Health authorities revealed Wednesday that the University of Kansas Medical Center and Childrens Mercy Kansas City will be bringing a COVID-19 vaccine trial to the Kansas City area.
Authorities stated the 2 healthcare facilities will lead the trial of an AstraZeneca vaccine in the area as part of the COVID-19 Prevention Network. The network, referred to as CoVPN, was developed by the National Institutes of Health (NIH) in response to the pandemic.

The specific vaccine is AZD1222, it was originally established by Oxford University prior to being purchased by AstraZeneca.
” This vaccine is very interesting,” stated Dr. Mario Castro on Mondays University of Kansas Health System Panel.
Castro is the vice chair for Clinical and Transitional Research and a pulmonologist at the University of Kansas School of Medicine Department of Internal Medicine.
” Theres been so much thrown at this coronavirus in regards to treatment and prevention, and we eventually know that the very best strategy for this infection is a vaccine,” Castro stated.
Authorities stated the vaccine is due to launch in mid-to-late August, and its the second of three stages for the trial funded by the NIH, and sponsored by AstraZeneca.
The study of the trial is focusing on efforts at more than 100 websites across the country.
Castro and Dr. Barbara Pahud, Research Director of Pediatric Infectious Diseases at Childrens Mercy, and Clinical Associate Professor of Pediatrics at the KU School of Medicine, will function as co-principal investigators to the trial.
” We are working to establish and perform studies to make sure comprehensive and quick evaluation of COVID-19 vaccines,” Pahud said. “Safety is our No. 1 top priority. I would not offer this vaccine if I were not prepared to take it myself.”.
The trial will involve around 30,000 individuals nationally– with around 1,500 of those participants originating from the Kansas-Missouri area.
Participants will be randomized to determine who receives the vaccine, and who gets a placebo. Once the trial is finished, participants getting the placebo will be qualified for the vaccine.
In a press release, Castro said outcomes of a pilot study into this vaccine, released just recently in The Lancet, showed appealing results on more than 1,000 clinical trial individuals. Side results were reported to be moderate, and included mostly headaches, body pains and tiredness.
” In truth, in over 1,000 patients, there were no severe negative events reported, which is extremely heartening,” Castro stated.
If you d like to volunteer for the trial to get the vaccine, you can register at the CoVPN website, just consist of a site referral as KUMC. Or, if you live in the Kansas City location, call Shelby for evaluating at 913-574-3006. and in Wichita, call 316-293-1833.

Health authorities announced Wednesday that the University of Kansas Medical Center and Childrens Mercy Kansas City will be bringing a COVID-19 vaccine trial to the Kansas City area.Officials said the two hospitals will lead the trial of an AstraZeneca vaccine in the region as part of the COVID-19 Prevention Network. Authorities stated the vaccine is due to launch in mid-to-late August, and its the second of 3 phases for the trial funded by the NIH, and sponsored by AstraZeneca. In a news release, Castro stated outcomes of a pilot research study into this vaccine, released just recently in The Lancet, showed appealing outcomes on more than 1,000 medical trial participants.

Health officials announced Wednesday that the University of Kansas Medical Center and Childrens Mercy Kansas City will be bringing a COVID-19 vaccine trial to the Kansas City area.Officials said the two medical facilities will lead the trial of an AstraZeneca vaccine in the region as part of the COVID-19 Prevention Network. Authorities stated the vaccine is due to launch in mid-to-late August, and its the second of 3 phases for the trial moneyed by the NIH, and sponsored by AstraZeneca. In a news release, Castro stated outcomes of a pilot research study into this vaccine, published recently in The Lancet, showed appealing outcomes on more than 1,000 clinical trial individuals. “In reality, in over 1,000 patients, there were no serious unfavorable occasions reported, which is extremely heartening,” Castro said.If you d like to volunteer for the trial to receive the vaccine, you can sign up at the CoVPN website, just consist of a website referral as KUMC. As soon as the trial is finished, individuals receiving the placebo will be qualified for the vaccine.